论文部分内容阅读
目的观察达英-35治疗多囊卵巢综合症(PCOS)的疗效。方法将36例确诊的PCOS患者于月经第5天开始服用达英-35,每日1片,连服21天为一个周期,停药待撤退性出血第5天开始下一周期。有20例服用3个周期,16例服用6-9个周期。每月记录经量、痤疮、多毛的变化,治疗前及治疗后测定黄体生成素(LH)、促卵泡激素(FSH)、雌二醇(E2)、睾酮(T)、催乳素(PRL)的变化及总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、载脂蛋白A(APOa)、载脂蛋白B(APOb)的变化;治疗前及治疗后行阴道B超检查,记录子宫大小、卵巢大小及卵泡数目。结果28例月经减少者中23例经量较前增多,20例痤疮者中17例治愈或基本治愈,14例多毛者有12例症状明显改善。血LH、FSH水平明显下降(P<0.01),LH/FSH恢复正常(P<0.01),T亦有明显降低(P<0.05)。LDL下降和HDL升高(P<0.01)。卵巢体积缩小,卵泡数明显减少(P<0.01)。结论达英-35治疗PCOS能有效改善症状,使异常升高的促性腺激素及雄激素恢复正常,不良反应少,适用于无生育要求及有生育要求患者促排卵前的准备。
Objective To observe the curative effect of Da Ying-35 in the treatment of polycystic ovary syndrome (PCOS). Methods Thirty-six patients with PCOS were started taking da-Ying-35 on day 5 of menstruation. One tablet per day was given for 21 consecutive days. The withdrawal was started on the fifth day of withdrawal bleeding. Twenty patients took three cycles and sixteen took 6-9 cycles. The amount of menstrual flow, acne and hirsutism were recorded every month. The levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2), testosterone (T) and prolactin (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL), apolipoprotein A (APOa) and apolipoprotein B Vaginal ultrasound before and after treatment, recording the size of the uterus, ovarian size and the number of follicles. Results Twenty-eight cases of menorrhagia with 23 cases of menstruation increased compared with the former, 20 cases of acne cured or basically cured in 17 cases, 14 cases of hairy have improved significantly in 12 cases. Blood LH and FSH levels decreased significantly (P <0.01), LH / FSH returned to normal (P <0.01), T also decreased significantly (P <0.05). LDL decreased and HDL increased (P <0.01). Ovarian volume decreased, the number of follicles was significantly reduced (P <0.01). Conclusion Da-Ying-35 treatment of PCOS can effectively improve the symptoms, the abnormal increase of gonadotropins and androgen return to normal, fewer adverse reactions, suitable for non-fertility requirements and fertility requirements of patients before ovulation preparation.